Greater depth of prostate-specific antigen (PSA) decline is associated with improved clinical outcomes among men treated with enzalutamide for nonmetastatic castration-resistant prostate cancer, according to a study published in the March issue of The Journal of Urology.
- Digital Rectal Exams Could Miss Early Prostate Cancers
- Men With Prostate Cancer Can Thrive for Years With Less Aggressive Treatment
- Plant-Based Diets Linked to Lower Risk of Prostate Cancer Progression and Recurrence
- Metastatic Hormone-Sensitive Prostate Cancer
- Magnitude of Reduction in PSA Level May Indicate Outcomes in Prostate Cancer